Order Article Reprints

Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, et al. The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. Vaccines. 2022; 10(2):158. https://doi.org/10.3390/vaccines10020158

Watanabe, Marika, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Wataru Hojo, Hironori Sakai, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, and et al. 2022. "The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation" Vaccines 10, no. 2: 158. https://doi.org/10.3390/vaccines10020158

Watanabe, M., Yakushijin, K., Funakoshi, Y., Ohji, G., Hojo, W., Sakai, H., Saeki, M., Hirakawa, Y., Matsumoto, S., Sakai, R., Nagao, S., Kitao, A., Miyata, Y., Koyama, T., Saito, Y., Kawamoto, S., Ito, M., Murayama, T., Matsuoka, H., & Minami, H. (2022). The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. Vaccines, 10(2), 158. https://doi.org/10.3390/vaccines10020158